+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the effectiveness of dotinurad compared with allopurinol in lowering serum uric acid levels in adults with gout-related hyperuricemia. This Phase 3 randomized study focuses on measuring the proportion of participants achieving target serum uric acid levels at Week 24. It aims to provide insights into treatment options for people living with gout. Participants will be randomly assigned to one of three groups one group will continue allopurinol at their current stable dose once daily through Week 64, while the other two groups will receive dotinurad with dose escalation over time. Dotinurad dosing starts at 1 mg daily for the first 4 weeks, increasing to 2 mg daily through Week 64 for one group, and for the other group, it increases from 1 mg daily for 4 weeks to 2 mg daily for 8 weeks, then 4 mg daily through Week 64. Throughout the study, participants will undergo regular assessments including serum uric acid level measurements and gout flare monitoring from baseline through Week 68. Safety will also be tracked by recording adverse events. The main outcome is the percentage of participants with serum uric acid below 6.0 mgdL at Week 24. The total study duration per participant extends up to approximately 68 weeks, with ongoing evaluations to assess gout flare frequency and other relevant outcomes.

Age: 18Years - 75YearsAll GendersPhase 3
119 locations
E

Actively Recruiting

Researchers are studying the safety and effectiveness of a minimally invasive device called the Alleviant ALV1 System in patients with chronic heart failure, specifically those with heart failure with preserved or mildly reduced ejection fraction HFpEFHFmrEF. This prospective, multicenter, randomized, double-blind trial compares the device procedure to a sham control in order to better understand its potential benefits and risks. Participants are randomly assigned to one of two groups. Those in the treatment group undergo cardiac imaging, femoral vein access, and receive the Alleviant ALV1 System device procedure, which creates an interatrial shunt. The control group undergoes cardiac imaging and femoral vein sheath placement without the device procedure. The study has a crossover design, allowing participants to experience both conditions during the trial. During the study, participants will have cardiac imaging and exercise right heart catheterization to monitor heart function and pressures. Researchers will evaluate a composite primary endpoint at 12 months to assess safety and efficacy. Participants will be monitored for ongoing health status while continuing stable guideline-directed medical therapy. The trial is expected to complete by December 2032.

Age: 40Years +All GendersPhase Not Applicable
93 locations